The European Alliance for Personalised Medicine will convene a dedicated ESMO session on “Personalised Oncology Across Health Systems: From Molecular Insight to Measurable Access” on Friday, 23 October 2026.
The session will examine how Europe can move beyond scientific discovery and ensure that personalised oncology becomes a measurable reality for patients across health systems. As molecular diagnostics, biomarker testing, liquid biopsy, synthetic data, digital pathology and innovative therapies continue to transform cancer care, the central question is no longer only what science can deliver, but whether health systems are ready to identify eligible patients, deliver the right test, interpret the result, act on treatment or trial eligibility, and measure whether access has improved.
The morning programme will focus on building the implementation backbone for personalised oncology. It will bring together European projects including SYNTHIA, BRECISE, SPARC, ON-COME and iBeChange, each contributing distinct but complementary insights into how innovation can be translated into practice. SYNTHIA will highlight the role of synthetic data in enabling research and decision-making while safeguarding privacy; BRECISE will explore biomarker-driven approaches and precision diagnostics; SPARC will address pathways for integrating personalised care into health systems; ON-COME will focus on improving outcomes through coordinated oncology care models; and iBeChange will examine behavioural, organisational and policy shifts needed to support adoption. Together, these initiatives will demonstrate how their outputs can support policy, clinical implementation, reimbursement, patient engagement and equitable access. Discussions will address synthetic data, biomarker validation, molecular diagnostics, prevention, supportive care, health literacy and health-system readiness.
The afternoon programme will apply these implementation questions to priority cancer areas. Sessions will focus on biomarker testing and liquid biopsy, pancreatic cancer, lung and breast cancer, and multiple myeloma, examining how health systems can better align diagnostics, molecular interpretation, treatment access, clinical trials, reimbursement and real-world evidence.
Throughout the day, the meeting will follow a practical pathway: Identify → Test → Interpret → Act → Measure. This framework will guide discussions on where patients are currently lost between diagnosis, testing, eligibility, treatment access, clinical trial referral, supportive care and outcomes measurement.
The session will close by defining a practical post-ESMO implementation agenda, including priorities for diagnostics, treatment access, reimbursement, data infrastructure, prevention, supportive care and equity. Expected outputs include a personalised oncology access statement, an eligibility-to-access pathway map, a policy communiqué and a stakeholder consultation route involving clinicians, patients, policymakers, payers, diagnostics leaders, researchers and innovation partners.
The central message is clear: personalised oncology will not be delivered by innovation alone. Europe’s leadership should be measured not only by the innovations it discovers or approves, but by whether patients can benefit from them in routine care.